×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Surajit Pal
Surajit Pal
Ads
USFDA issues import alert for Divi's Labs Vizag unit
Price erosion won't impact generic cos in US: Dishman Pharma
Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal
Trump's 'Make in US' plan a worry for pharma cos: Surajit Pal
Pharma price collusion charges tough to prove: Prabhudas
Crack The Code: Decoding pharma sector
US FDA completes Aurobindo's Unit 4 audit; to help boost US biz
Aurobindo's topline can swell by $350 m with Teva buy: PL
Sun Pharma's topline may suffer; like Aurobindo, Glenmark:Expert
Pharma biz to drive Jubilant Life's future growth: Surajit Pal
Not positive on Lupin's US business: Surajit Pal
After DRL-Teva, expect more M&A action in pharma: Prabhudas
See Lupin's earnings growing only 8-12%: Prabhudas Lilladher
Thyrocare biz looks convincing; subscribe to its IPO: Experts
Aim is to prevent rampant use of antibiotics: P Lilladher
Ranbaxy effect playing on Sun Pharma's margins: Pros
'Lupin Q4 misses estimates, stock upside potential capped'
See 10% overall growth for Sun-Ranbaxy entity: Surajit Pal
Hold Sun Pharma, says Surajit Pal
Accumulate Sun Pharmaceutical Industries: Surajit Pal
Sun Pharma to buy GSK's opiates business in Australia
See Sun-Ranbaxy divesting 7 brands by March: Surajit Pal
US FDA initiates audit of Ipca's Indore SEZ; sales hit seen
Here's how experts read Ranbaxy's Q2FY15 earnings
Here's what experts make of Lupin's Q2 earnings
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio